Company Profile
Business Strategy
Management
Contact
Imprint
MediGene AG: Webcast of the Analyst conference call in Frankfurt
on May 15, 02:30 p.m.(CEST)

MediGene Concludes Agreement with Juste for the Commercialization of VeregenŽ in Spain and Portugal  more
MediGene: Presentation of EndoTAG(TM)-1 and oHSV Results at the 2009 ASCO Annual Meeting  more
FDA Grants Orphan Drug Designation for MediGene's Drug Candidate EndoTAG(TM)-1  more
MediGene AG Reports Three Month 2009 Results: Revenue and Result Significantly Improved  more

MediGene's vision is the expansion of the potentials in medicine
by means of utilizing biotechnology in a responsible manner.
We apply state-of-the-art technologies in the development of
innovative drugs for the treatment of cancer and autoimmune
diseases. MediGene pursues the strategy of integrating all core
areas of a modern biopharmaceuticals company from research to
drug development and commercialization.